<DOC>
	<DOCNO>NCT00362037</DOCNO>
	<brief_summary>- To evaluate Blood Pressure ( BP ) reduction target value ( BP ≤ 140/90 mm Hg non-diabetic patient , ≤ 130/80 mm Hg diabetic patient ) . - To emphasize evaluate benefit Irbesartan reduction leave ventricular mass index hypertensive patient leave ventricular hypertrophy . - To demonstrate safety Irbesartan population .</brief_summary>
	<brief_title>I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Patients prove mild moderate Hypertension . Patients must leave ventricular mass index &gt; 130g/m2 men , &gt; 100g/m2 woman , evidence echocardiography inclusion . Newly diagnose `` naïve '' hypertensive patient ( prior treatment hypertension ) . OR , Patients receive antihypertensive agent ( maximum two agent include one diuretic ) blood pressure target achieve , yet , investigator 's opinion , patient would benefit switch study medication . These patient undergo wash period le 7 day prior enrollment . Severe hypertension ( Systolic BP ≥ 180 mm Hg Diastolic BP ≥ 110 mm Hg ) . Patients leave ventricular ejection fraction &lt; 45 % . Patients severe leave ventricular hypertrophy . Patients know secondary hypertension ( another cause type 2 Diabetes Mellitus ) . Diabetic patient HbA1c &gt; 10 % . Significant chronic renal impairment ( Serum creatinine &gt; 2.0 mg/dL ) . Significant liver disease show SGPT/SGOT ( ALT/AST ) &gt; 2.5 time upper limit normal range . Currently pregnant lactating female . Women childbearing potential protected effective contraceptive method birth control and/or unwilling unable test pregnancy . Any patient need combination antihypertensive therapy start ( medical point view his/her physician ) . Known hypersensitivity irbesartan , ARBs ( Angiotensin Receptor Blockers ) , hydrochlorothiazide , thiazide diuretic . Patients malignancy past 5 year , know collagen disease severe cardiac , cerebrovascular gastric disease . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>